Why IMU is a multi multi bagger, page-31371

Here's a conspiracy theory to add to the insanity.
Jen Chow (ex-CHM) was a Precision operative, her mission was to find a buyer for a promising but problematic asset azer-cel in the large B-cell lymphoma (LBCL) population.
CHM appears the obvious fit but has no cash.
Chow realises that IMU has cash and Chong is facing a huge news flow void with B-cell in no-mans land, CF-33 moving more slowly than anticipated and the jewel in the crown onCARlytics even further off with baby step protocols governing such a paradigm shifting endeavour.

The hook: Chow pitches Leslie & Paul I may have something that will fill that news flow void and give the market something to digest and provide a smoke screen for the slow progress of oncolytics & onCarlytics plus I can get CHM some funds win win.

The line: You gotta move fast on this have a word with some "friends" get them to look over the data and get back to me.

Excitable Chong jumps on the bait
Sydney, Australia, 16 August 2023: Imugene MD & CEO, Ms Leslie Chong said, “Azer-cel has one of the most extensive clinicaldata sets for a CD19 directed allogeneic cell therapy, a fast-to-market developmentstrategy and a potential registration-enabling clinical trial in 2024 for patients with 3rdand 4th line DLBCL. We plan to complete the ongoing multi-centre Phase 1b(ClinicalTrials.gov ID NCT03666000) study using the recommended Phase 2 regimen aswe prepare for the start of a potential registrational study at the earliest opportunity. Weare very excited as azer-cel has the potential to be the first approved allo CAR T"
"A positive meeting was held with the FDA in June 2023 to seek guidance for entering aPhase 2 registration study."

Sydney, Australia, 28 September 2023: "US Food and DrugAdministration (FDA) has transferred the Investigational New Drug (IND) Application forits allogeneic CD19 CAR T azer-cel from Precision Biosciences Inc. (NASDAQ GS: DTIL)to Imugene, following the exclusive worldwide license acquired in August."
Imugene MD & CEO, Ms Leslie Chong said, “We are actively progressing the ongoingmulti-centre Phase 1b (ClinicalTrials.gov ID NCT03666000) study using therecommended Phase 2 regimen of azer-cel as we prepare for the start of a potentialPhase 2 registrational study at the earliest opportunity,

News of registrational trials will fill the news flow gap at IMU while oncolytics & onCarlytics through the hoops.

Chow mission here now complete and she departs CHM
Sydney, Australia, 1 May 2024: "Ms. Jennifer Chow has given notice of her resignationas Chief Executive Officer and Managing Director of the Company. It is expected that Ms. Chow willleave the Company on May 24, 2024."

The problem with Azer-cel comes to light:
SYDNEY, Australia, 2 September 2024: “I am proud of our clinical development team who assessed ways to enhance azer-cel'sdurability of response, as one of the biggest challenges in CAR T therapy is ensuring thatthe modified T-cells stay in the body long enough to kill cancer cells,” said Leslie Chong,Managing Director and CEO of Imugene. “To maximise the response rates and durabilityfurther, we added a very low dose of IL-2 to the regimen in Cohort B. We are pleased withthe results, which suggest improved outcomes in patients, and we look forward toamassing more data using this dosing regimen. We will continue to seek biomarkerevidence from Cohort B patients that suggest our strategy is improving the performanceof azer-cel.”

Fortunately for Chong one of the brains trust dropped in some IL2 and Cohort B become the way forward had it not been for that "potential" masterstroke the Azer-cel program would have gone the way of Cohort A whose fate like a lot of other outcomes at IMU are unknown!!

Shareholders have every right to feel aggrieved considering the bullish proclamations for 2024 by Chong as highlighted above and the liberal use of weasel words in every announcement.

Yet here we are and Leslie has no idea why the market is punishing IMU